NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
Clinical Trials
10 trialsNCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT01855451 2022-11-18
HPVOropharynx
Trans Tasman Radiation Oncology Group
Phase 3 Unknown
NCT05074966 2021-10-12
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
ChineseAMS
Phase 3 Unknown
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04509635 2020-08-12
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Fudan University
Phase 3 Unknown
NCT00999700 2017-09-05
INTERCEPTOR
Gruppo Oncologico del Nord-Ovest
Phase 3 Unknown
NCT02633176 2015-12-17
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT00433927 2014-03-14
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Phase 3 Unknown
NCT00482222 2013-01-23
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
Phase 3 Unknown